Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics Inc. (NASDAQ: STIM) pioneers FDA-cleared transcranial magnetic stimulation (TMS) therapies for major depressive disorder and neurohealth conditions. This dedicated news hub provides investors and healthcare professionals with essential updates about the company's noninvasive treatment innovations, financial performance, and clinical advancements.
Discover comprehensive coverage of STIM's regulatory milestones, including NeuroStar system clearances, alongside analyses of quarterly earnings and strategic collaborations. The page consolidates official press releases about TMS therapy adoption across treatment networks and developments in adolescent mental health applications.
Key updates include FDA decision alerts, partnership announcements with clinical providers like Greenbrook TMS, and presentations of new outcomes data from the world's largest depression treatment registry. Investors gain insights into operational expansions while medical professionals track evidence-based protocol enhancements.
Bookmark this page for streamlined access to Neuronetics' verified corporate communications and therapeutic innovation updates. Regularly refreshed content ensures you stay informed about advancements in non-pharmaceutical depression treatment technologies.
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, a medical technology company focused on neurohealth, announced it will release its first quarter 2023 financial and operating results before the market opens on May 9, 2023. A conference call is scheduled for the same day at 8:30 a.m. Eastern Time to discuss these results.
The call will be accessible via a live webcast and participants can register for phone access in advance. Neuronetics emphasizes the importance of mental health, offering its NeuroStar Advanced Therapy, a non-invasive treatment for major depressive disorder (MDD) and other conditions. NeuroStar has delivered over 5.3 million treatments and is backed by extensive clinical data, making it a leader in transcranial magnetic stimulation (TMS) therapies.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
